Legis Daily

To improve patient access to emerging medication therapies by clarifying the scope of permitted health care economic and scientific information communications between biopharmaceutical manufacturers and population health decision makers.

USA115th CongressHR-2026| House 
| Updated: 1/17/2018
Brett Guthrie

Brett Guthrie

Republican Representative

Kentucky

Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Pharmaceutical Information Exchange Act This bill amends the Federal Food, Drug, and Cosmetic Act to allow information about a new investigational medication or the investigational use of a medication approved by the Food and Drug Administration to be provided to health care entities if the information is based on reliable scientific evidence.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Apr 6, 2017
Introduced in House
Apr 6, 2017
Referred to the House Committee on Energy and Commerce.
Apr 7, 2017
Referred to the Subcommittee on Health.
Jan 17, 2018
Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 18 - 14 .
Jan 17, 2018
Subcommittee Consideration and Mark-up Session Held.
  • April 6, 2017
    Introduced in House
  • April 6, 2017
    Referred to the House Committee on Energy and Commerce.
  • April 7, 2017
    Referred to the Subcommittee on Health.
  • January 17, 2018
    Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 18 - 14 .
  • January 17, 2018
    Subcommittee Consideration and Mark-up Session Held.

Health

Drug safety, medical device, and laboratory regulationFraud offenses and financial crimesHealth information and medical recordsMedical research

To improve patient access to emerging medication therapies by clarifying the scope of permitted health care economic and scientific information communications between biopharmaceutical manufacturers and population health decision makers.

USA115th CongressHR-2026| House 
| Updated: 1/17/2018
Pharmaceutical Information Exchange Act This bill amends the Federal Food, Drug, and Cosmetic Act to allow information about a new investigational medication or the investigational use of a medication approved by the Food and Drug Administration to be provided to health care entities if the information is based on reliable scientific evidence.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Apr 6, 2017
Introduced in House
Apr 6, 2017
Referred to the House Committee on Energy and Commerce.
Apr 7, 2017
Referred to the Subcommittee on Health.
Jan 17, 2018
Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 18 - 14 .
Jan 17, 2018
Subcommittee Consideration and Mark-up Session Held.
  • April 6, 2017
    Introduced in House
  • April 6, 2017
    Referred to the House Committee on Energy and Commerce.
  • April 7, 2017
    Referred to the Subcommittee on Health.
  • January 17, 2018
    Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 18 - 14 .
  • January 17, 2018
    Subcommittee Consideration and Mark-up Session Held.
Brett Guthrie

Brett Guthrie

Republican Representative

Kentucky

Health Subcommittee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Drug safety, medical device, and laboratory regulationFraud offenses and financial crimesHealth information and medical recordsMedical research